Bellwether Advisors’s Royalty Pharma RPRX Stock Holding History

Bellwether Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-68	Closed	-$2K	–	546
2022 Q3	$2K	Buy	+68	New	+$2.9K	﹤0.01%	400

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellwether Advisors's RPRX Position: Q4 2022 in Review

Bellwether Advisors sold out of Royalty Pharma (RPRX) in Q4 2022, closing a stake of 68 shares — an estimated $2K sold.

Bellwether Advisors first reported a position in RPRX in Q3 2022 and held it in 1 quarter. The position peaked at $2K in Q3 2022. 336 funds tracked by Wall St. Rank hold RPRX as of Q4 2022.

Bellwether Advisors reported no remaining Royalty Pharma position as of Q4 2022 after selling out during the quarter.
Bellwether Advisors sold 68 Royalty Pharma shares in Q4 2022, an estimated $2K.
Bellwether Advisors first reported a position in Royalty Pharma in Q3 2022 and held it in 1 quarter.
Bellwether Advisors's Royalty Pharma position peaked at $2K in Q3 2022.
336 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2022.

Based on Bellwether Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.